PMID

Data

Article Title

Organization

Substituted oxopyridine derivatives and use thereof as factor XIa/plasma

Bayer Pharma Aktiengesellschaft

Tricyclic pyrido-carboxamide derivatives as rock inhibitors

Bristol-Myers Squibb

TrKA kinase inhibitors, compositions and methods thereof

Merck Sharp & Dohme

Triazole compounds as T-type calcium channel blockers

Idorsia Pharmaceuticals

3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds

Parion Sciences

LSD1 inhibitors

Mirati Therapeutics

Pyrazole orexin receptor antagonists

Merck Sharp & Dohme

Treatment of respiratory disorders using ROR-gamma inhibitors

Glenmark Pharmaceuticals

Therapeutically active compositions and their methods of use

Agios Pharmaceuticals

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

Bristol-Myers Squibb

Tricyclic heterocycles as BET protein inhibitors

Incyte

Inhibitors of the renal outer medullary potassium channel

Merck Sharp & Dohme

Compounds useful as immunomodulators

Bristol-Myers Squibb

Autotaxin inhibitor compounds

Pharmakea

1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties

The Regents of The University of Michigan

Substituted 2-azabicycles and their use as orexin receptor modulators

TBA

Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors

Incyte

Protein kinase inhibitors

Pharmascience

Inhibitors of plasma kallikrein

Kalvista Pharmaceuticals

Metalloenzyme inhibitor compounds

Mycovia Pharmaceuticals

Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof

Merck Sharp & Dohme

Inhibitors of human immunodeficiency virus replication

Viiv Healthcare UK (NO.5)

Compounds, compositions and methods useful for cholesterol mobilization

Cerenis Therapeutics Holding

Btk inhibitors

Merck Sharp & Dohme

Factor XIA inhibitors

Merck Sharp & Dohme

Quinazolines as potassium ion channel inhibitors

Bristol-Myers Squibb

Amino-substituted heterocyclic derivatives as sodium channel inhibitors

Almirall

Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators

Reset Therapeutics

Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.

Schering-Plough Research Institute

Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.

Johnson & Johnson Pharmaceutical

Identification of small molecule agonists of the orphan nuclear receptors liver receptor homolog-1 and steroidogenic factor-1.

University of Southampton

Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.

Abbott Laboratories

Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.

Bristol-Myers Squibb

Beta-substituted cyclohexanecarboxamide cathepsin K inhibitors: modification of the 1,2-disubstituted aromatic core.

Merck Frosst Centre For Therapeutic Research

A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.

Merck Frosst Centre For Therapeutic Research

Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.

Merck Frosst Centre For Therapeutic Research

Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.

Merck Frosst Centre For Therapeutic Research

Cyclic ketone inhibitors of the cysteine protease cathepsin K.

Gsk

(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.

Astellas Pharma

Synthesis and characterization of nonsteroidal glucocorticoid receptor modulators for multiple myeloma.

Ligand Pharmaceuticals

N(4)-Phenyl modifications of N(2)-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease.

Nih

Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.

Nih

Pyrazole inhibitors of HMG-CoA reductase: An attempt to dramatically reduce synthetic complexity through minimal analog re-design.

Pfizer

Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.

Pfizer

Thermodynamic characterization of the binding of nucleotides to glycyl-tRNA synthetase.

Medical College of Ohio

The 1.15A crystal structure of the Staphylococcus aureus methionyl-aminopeptidase and complexes with triazole based inhibitors.

Morphochem

Design and Synthesis of HIV-1 Protease Inhibitors Incorporating Oxazolidinones as P2/P2' Ligands in Pseudosymmetric Dipeptide Isosteres.

University of Massachusetts Medical School

Discovery of Novel Benzimidazoles as Potent Inhibitors of TIE-2 and VEGFR-2 Tyrosine Kinase Receptors.

Gsk